Article – Anpac Bio

AnPac Bio Files Coronavirus Detection Patent and Initiates Related Research Project

FOR IMMEDIATE RELEASE

AnPac Bio Files Coronavirus Detection Patent and Initiates Related Research Project

San Jose, CA, February 27, 2020 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, today announced that it has filed a provisional patent application on the use of AnPac Bio’s novel detection technology, methods and apparatus for coronavirus detection with the US Patent Trademark and Office on February 10, 2020, which could later lead to formal patent applications in China and other countries. AnPac Bio also announced today that it has entered into a project cooperation agreement with a hospital in China to conduct research studies on the ability of AnPac Bio’s CDA (Cancer Differentiation Analysis) technology to detect the risk of coronavirus, which is expected to be a very challenging and long term project for AnPac Bio.

While AnPac Bio’s focus has been on cancer risk assessment, AnPac Bio’s biophysical property-based CDA technology has also been evaluated for other major non-cancerous diseases, and valuable information and data have been collected for clinical samples on major non-cancerous diseases. “Exploring the CDA technology’s ability to detect the risk of major non-cancerous diseases and broadening its product offerings for other life threatening diseases has been part of AnPac Bio’s business strategies for years,” commented AnPac Bio’s Chairman and CEO, Dr. Chris Yu.

About AnPac Bio

AnPac Bio is a biotechnology company focused on early cancer screening and detection, with 121 issued patents as of September 30, 2019. With two certified clinical laboratories in China and one CLIA registered clinical laboratory in the United States, AnPac Bio performs a suite of cancer screening and detection tests, including CDA (Cancer Differentiation Analysis), bio-chemical, immunological, and genomics tests. In a recent market research report by Frost & Sullivan, AnPac Bio ranked second worldwide among companies offering next-generation early cancer screening and detection technologies in terms of the number of clinical samples for cancer screening and detection, based on approximately 35,000 clinical samples as at June 30, 2019. AnPac Bio’s CDA technology has been shown in retrospective validation studies to be able to detect the risk of over 20 different cancer types with high sensitivity and specificity.

For more information, please visit: https://www.Anpacbio.com.

For investor and media inquiries, please contact:

Company:

Phil Case, Marketing and Investor Relations

Phone: +1-267-810-6776 (US)

Email: [email protected]

Investor Relations:

Ascent Investor Relations LLC
Tina Xiao, President
Phone: +1-917-609-0333 (US)
Email: [email protected]

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are made under the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and are relating to the Company’s future financial and operating performance. The Company has attempted to identify forward-looking statements by terminologies including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “target,” “aim,” “predict,” “outlook,” “seek,” “goal” “objective,” “assume,” “contemplate,” “continue,” “positioned,” “forecast,” “likely,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company’s control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to be materially different from those expressed or implied by any forward-looking statement. Known and unknown risks, uncertainties and other factors include, but are not limited to, the implementation of our business model and growth strategies; trends and competition in the cancer screening and detection market; our expectations regarding demand for and market acceptance of our cancer screening and detection tests and our ability to expand our customer base; our ability to obtain and maintain intellectual property protections for our CDA technology and our continued research and development to keep pace with technology developments; our ability to obtain and maintain regulatory approvals from the NMPA, the FDA and the relevant U.S. states and have our laboratories certified or accredited by authorities including the CLIA; our future business development, financial condition and results of operations and our ability to obtain financing cost-effectively; potential changes of government regulations; general economic and business conditions in China and elsewhere; our ability to hire and maintain key personnel; and our relationship with our major business partners and customers. Additionally, all forward-looking statements are subject to the “Risk Factors” detailed from time to time in the Company’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

ANPAC BIO APPOINTS NOBEL PRIZE WINNER DR. MICHAEL LEVITT AS CHIEF CONSULTANT TO LEAD ANPAC’S PIONEERING EFFORTS IN CANCER SCREENING

San Jose, CA – December 11, 2019 – Anpac Bio-Medical Science Co., Ltd. (“Anpac Bio” or the “Company”) announced today the appointment of Professor Michael Levitt of Stanford University to be the Chief Consultant of Anpac Bio’s Innovation and Technical Advisory Board. Dr. Levitt received the 2013 Nobel Prize in Chemistry for the development of multiscale models for complex chemical systems. Dr. Levitt’s role will be to help strengthen Anpac Bio’s patented CDA (Cancer-Differentiation Analysis) technology, which can detect the risk of up to 26 cancer types using a single blood test. Anpac Bio provides its CDA tests commercially in China and is currently working to enter the market in the United States.

Anpac Bio’s Chairman and CEO, Chris Yu, commented, “Anpac is excited to be working with Dr. Levitt on our ground-breaking technology. Our innovative biophysical approach to cancer screening and detection is complementary with Dr. Levitt’s background in quantum mechanics, chemistry, and structural biology. We believe that Dr. Levitt’s contributions will help us to achieve further market penetration in China and will assist us in our entrance in the United States through clinical trials and additional academic collaborations.”

Dr. Levitt has previously served on the Scientific Advisory Boards of DuPont Merck Pharmaceuticals, AMGEN (NASDAQ: AMGN), PDL Biopharma (NASDAQ: PDLI), as well as many other well-known companies throughout his career. Dr. Levitt received his PhD from Cambridge University in 1972 and was a postdoctoral scholar at the Weizmann Institute of Science in Israel from 1972 to 1974. Dr. Levitt joined the Department of Structural Biology at Stanford in 1987.

About Anpac Bio

Anpac Bio is a biotechnology company focused on early cancer screening and detection. With two certified clinical laboratories in China, Anpac Bio performs a suite of cancer screening and detection tests, including CDA, bio-chemical, immunological, and genomics tests. In a recent market research report by Frost & Sullivan, Anpac Bio ranked second worldwide among companies offering next-generation early cancer screening and detection technologies in terms of the number of clinical samples for cancer screening and detection, based on approximately 35,000 clinical samples as at June 30, 2019. These clinical samples demonstrated that Anpac Bio’s CDA technology could detect the risk of over 20 different cancer types with high sensitivity and specificity.

Safe Harbor Statement

This announcement contains forward-looking statements, including statements about the Company’s business outlook, strategy and market opportunity, and statements that may suggest trends for its business. These statements are individually and collectively forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are made only as of the date of this announcement and are based on estimates and information available to the Company at the time of this announcement. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict and may be beyond the Company’s control. Therefore, prospective investors are cautioned that actual results may differ materially from those set forth in any forward-looking statements herein. Except as otherwise required by applicable securities laws, the Company disclaims any intention or obligation to publicly update or revise forward-looking statements, whether as a result of new information, future events or otherwise.

Anpac Bio Launches Major U.S. Expansion, Starting 2nd U.S. Clinical Lab in Philadelphia

Anpac Bio Launches Major U.S. Expansion, Starting 2^nd U.S. Clinical Lab in Philadelphia

SAN JOSE, California, October 14, 2019 – After winning a major award from the U.S. Department of Commerce as “Minority Health Products and Services Firm of the Year,” and obtaining CLIA certification for its clinical laboratory in San Jose earlier this year, Anpac Bio-Medical Science Co., Ltd. (“Anpac Bio”), today announced a major expansion in the U.S. by selecting Philadelphia as its second clinical laboratory site and new U.S. corporate headquarters.

Of this expansion, CEO, Dr. Chris Yu, remarked, “With our leading-edge technology extensively validated by 40,000 blood samples from our research studies and 100,000 blood samples from our cancer risk assessment using CDA-based tests in China, we are now fully committed to R&D and market penetration in the U.S. By placing our second clinical laboratory in Philadelphia, we can work with our hospital principal investigators and partners in the East Coast much more closely and effectively.”

Anpac Bio’s new U.S. corporate headquarters and laboratory will be centrally located in the Mid-Atlantic region and easily accessible to key markets. The 7,000 square foot office and lab space will be located in the Spring House Innovation Park which also houses the Jefferson Institute for Bioprocessing. Philadelphia was recently named the latest of the Big4Bio regions for its innovation in the life sciences sector and home to more than 800 life sciences companies and 15 major health systems.

“We are very excited to be moving forward with our U.S. corporate headquarters and laboratory in Pennsylvania. The state has a mature life sciences ecosystem and a supportive start-up environment that will allow our U.S. business to lay the foundation for future success”, stated Shaun Gong, Anpac’s U.S. President.

Anpac Bio is a leading biotechnology company focused on early cancer screening and detection. With multiple certified clinical laboratories in China, Anpac Bio markets a suite of cancer screening and detection tests, including CDA, bio-chemistry, immunology, and genomics tests. In a recent market research report by Frost & Sullivan, Anpac Bio ranked second worldwide among companies offering next-generation early cancer screening and detection technologies, based on approximately 35,000 clinical samples as at June 30, 2019. These clinical samples demonstrated that AnPac Bio’s CDA technology could detect the risk of over 20 different cancer types with high sensitivity and specificity rates.

For further information visit: AnpacBio.com or contact Phil Case: [email protected] or 801.362.9991.

###

Anpac Bio Gains U.S. CLIA Lab Certification

AnPac Bio Gains U.S. CLIA Lab Certification

SAN JOSE, California, September 26, 2019 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio”), a biotechnology company focusing on early cancer screening and detection, announced that the company’s United States subsidiary, has received a certificate of registration under the U.S. Clinical Laboratory Improvement Amendments of 1988, or CLIA, for its commercial laboratory in San Jose, California.

“We are pleased about the CLIA registration for our laboratory in San Jose, California,” states Dr. Chris Yu, AnPac Bio’s Chairman and CEO. “We are starting clinical research efforts and studies on our CDA in the United States, and we plan to commercialize our CDA technology in the United States in the future.”

AnPac Bio is a biotechnology company focused on early cancer screening and detection. The company markets and sells in China a multi-cancer screening and detection test that uses its proprietary and innovative cancer differentiation analysis, or CDA, technology and test to detect and assess an individual’s overall cancer risk with high accuracy, including early stage cancer. Comprehensive research validity data from approximately 40,000 research samples processed has demonstrated that AnPac Bio’s CDA technology can detect the risk of 26 different cancers, including early stage cancers, from a standard blood sample. As of June 30, 2019, AnPac Bio had filed over 200 patent applications worldwide, with 116 granted, including 54 in greater China (including seven in Taiwan) and 16 in the United States.

Anpac Bio has presented CDA research results before the American Society of Clinical Oncology and other medical conferences as well as in medical journal supplements. Multi-award winning, the company has received the “Outstanding Technology Innovation Award” in 2016 at the Nobel Prize Laureate Medical SummitNobel Prize Laureate Medical Summit; named, “Most Promising Early Cancer Screening Enterprise” in 2017 at the China & U.S. Precision Medicine Industry forum; was bestowed the international, “Big Innovation Award” by Business Intelligence Group in 2018, and “World Changing Ideas Honorable Mention” by Fast Company in 2019; and named by the U.S. Department of Commerce, Minority Business Development Agency in 2018 as the national, “Minority Health Products and Services Firm of the Year.”

Currently, AnPac Bio has entered into research agreements with U.S. universities and academic medical centers, and we are in discussions with other U.S. hospitals, medical institutions, contract research organizations, or CROs, managed care companies and other health organizations, to conduct research studies on our CDA technology in this laboratory.

For further information please visit: AnPacBio.com or contact Phil Case at [email protected] or 801.362.9991

###

Northwestern’s Dr. Lee Shulman Joins Anpac Bio Technical Advisory Board

SACRAMENTO, Calif., Oct. 23, 2018 — Dr. Chris Yu, Chief Executive Officer of international life sciences corporation, Anpac Bio-Medical Science Company (Anpac Bio), announced today that Northwestern University’s Dr. Lee P. Shulman, MD, FACMG, FACOG, has joined Anpac Bio’s Technical Advisory Board (TAB).

Northwestern Universitys Dr. Lee P. Shulman, MD, is the newest member of Anpac Bio-Medical Science Company’s #AnpacBio Technical Advisory Board. Shulman will be studying Anpac Bios Cancer Differentiation Analysis (CDA) liquid biopsy technologys potential applications for reproductive cancer screeningparticularly ovarian cancers. Anpac Bio’s liquid biopsy technology identifies 26+ different cancers with a single, standard blood test; usually at its earliest stages. More Info: AnpacBio.com.

It was due to Dr. Shulman’s extensive, award-winning research experience and reputation for identifying innovative solutions to fight disease that prompted the Anpac Bio TAB invitation. Shulman will be studying Anpac Bio’s “Cancer Differentiation Analysis” (CDA) liquid biopsy technology’s potential applications for reproductive cancer screening – particularly ovarian cancers. Among Shulman’s accomplishments:

The Anna Ross Lapham Professor in Obstetrics and Gynecology and Chief, Division of Clinical Genetics
Director, Northwestern Ovarian Cancer Early Detection and Prevention Program
Co-Director, Cancer Genetics Program – Robert S. Lurie Comprehensive Cancer Center
Feinberg School of Medicine of Northwestern University
Medical Director, Insight Medical Genetics and Reproductive Genetics Innovations
Adjunct Professor, Department of Medicinal Chemistry and PharmacognosyUniversity of Illinois at Chicago College of PharmacyChicago, Illinois
President, Central Association of Obstetricians and Gynecologists

Since 2008, Anpac Bio pioneered liquid biopsy research for cancer screening. Comprehensive research validity data from 100,000+ human cases processed (to date), demonstrate CDA diagnostics consistently detects 26+ different cancers — with 75%-90% sensitivity and specificity rates — usually identifying the disease at the earliest stages. And it does so without any harmful patient side effects; generating far fewer “false positives”; at a cost, substantially lower than traditional testing (such as imaging); and generating results within minutes of sample submission. Anpac Bio has filed 250+ CDA-related patent applications worldwide – 101+ issued by 20 countries (to date); and is fully-commercialized and earning liquid-biopsy screening revenue.

“Our Anpac Bio team is pleased to welcome Dr. Shulman as our newest Technical Advisory Board Member,” states Dr. Yu. “Dr. Shulman’s extensive reproductive cancer experience is of particular interest to our company. Too often, ovarian and other similar cancers are caught very late stage, when medical professionals have few options to treat the disease. However, our Anpac Bio technology is consistently generating outstanding results identifying early stage reproductive cancers. So, we are excited Dr. Shulman will be testing our equipment against the current, traditional screening methods; as well as advising us on how we can best support medical professionals’ efforts to catch the diseases and save their patients!”

Anpac Bio & UC Davis Names 2018 ‘Anpac Bio Innovation & Entrepreneurship Scholars’

Fellowships Fund University of California Entrepreneurship

SACRAMENTO, Calif.–(BUSINESS WIRE)–Anpac Bio-Medical Science Company, and the University of California, Davis Mike and Renee Child Institute for Innovation and Entrepreneurship (UCDMRCIIE) selected five accomplished, University of California (UC) scientists to be the 2018 “Anpac Bio-Medical Innovation & Entrepreneurship Scholars” (ABIES); and attend the prestigious University of California Entrepreneurship Academy (UCEA).

Anpac Bio-Medical Science Company, and the University of California, Davis Institute for Innovation and Entrepreneurship, selected five accomplished, University of California scientists to be the 2018 “Anpac Bio-Medical Innovation & Entrepreneurship Scholars”; and attend the prestigious University of California Entrepreneurship Academy. Pictured here (left-to-right), Anpac Bio Scholar Adam Contreras, Marketing Assistant Allison Steele, Academy Attendee Ilse Manuela Pastor, Scholar Alireza Tafazzol, Anpac Bio CMO Drisha Leggitt, Scholars Amir Bolandparvaz, Hilal Cansizoglu, and Marwa Zafarullah. Five ABIES winners are selected annually from among dozens of California graduates/undergraduates, postdoctoral research fellows, and life-sciences and/or biomedical engineering faculty, to receive the Anpac Bio Scholar fellowship and attend the UC Entrepreneurship Academy – considered one of the UC’s premiere programs for commercializing science and engineering innovations. (Photo: Business Wire)

Anpac Bio pledged $50,000 to underwrite two UCDMRCIIE programs annually: UCEA fellowships and the Biomedical and Engineering Entrepreneurship Academy launch event.

The five ABIES winners are selected annually from among dozens of California graduates and undergraduates, postdoctoral research fellows, and life-sciences and/or biomedical engineering faculty. Considered one of UC’s premiere programs for commercializing science and engineering innovations, the UCEA is a springboard for moving research out of the lab and into the world, providing deep immersion in business planning for aspiring and early-stage scientific innovators.

“Our company is very proud to sponsor five such talented and promising University of California students to be ‘Anpac Bio Scholars’ this year,” states Drisha Leggitt, Anpac Bio Chief Marketing Officer. “Anpac Bio supports the UCD Center for Innovation and Entrepreneurship because we believe to foster and achieve true, game-changing scientific innovation, we must simultaneously provide the entrepreneurs with the tools and skills needed to successfully integrate their solutions into the global marketplace. As our 2018 ‘Scholars’ all display the unique skills of scientific excellence, creativity, motivation, and dedication, Anpac Bio is pleased to provide these UC fellowships to help inspire and prepare these talented scientists for success!”

2018 UC “Anpac Bio Innovation & Entrepreneurship Scholars”:

AMIR BOLANDPARVAZ

PhD Candidate – Biomedical Engineering Business Development

Amir earned his B.S. in Bioengineering from UC San Diego; and matriculated at UC Davis to pursue a PhD in Biomedical Engineering. His research focuses on developing a therapeutic for autism. As a Business Development Fellow, he hopes to further understand the dynamics of the biotechnology industry and pursue multidisciplinary and translation research to improve human health.

HILAL CANSIZOGLU

Postdoctoral Scholar – Electrical Engineering

Hilal research focuses on engineering low-cost materials for high speed optical communication networks using nanotechnology. She manages a group of graduate and undergraduate students, mentoring and guiding for specific research goals and dissemination of project results. Hilal holds a B.S. in Physics; M.S. in Electrical Engineering; and a PhD degree in Applied Physics.

ADAM CONTRERAS

Postdoctoral Scholar – Institute for Regenerative Cures

Adam researches stem cell therapies that involve the use of electricity to control stem cell behaviors. Prior to joining the Institute for Regenerative Cures, he received a B.S. in Biochemistry from Texas State University; and a PhD in Molecular Biology from UC Davis. In his new position, he will seek to develop new tools and applications for the fields of stem cell therapy and regenerative medicine.

ALIREZA TAFAZZOL

PhD Candidate – Biomedical Engineering

Alireza uses computational techniques and quantum chemistry equations to design novel therapeutic drugs for various diseases such as cancer. He designs potent drugs to activate patients’ immune cells to fight back cancerous cells. Alireza holds a B.S. in Mechanical Engineering; and a M.S. in Biomechanics.

MARWA ZAFARULLAH

PhD Candidate – Integrative Genetics & Genomics Keller

Marwa Zafarullah is a third year Ph.D. in the Integrative Genetics and Genomics (IGG) graduate program. She earned her Bachelor’s in Agricultural Sciences from the University of Agriculture, Faisalabad, Pakistan; and her Master’s in IGG from UC, Davis. She is currently working towards the development of a Biomarker for the early diagnosis and progression of a Neurological Disorder called Fragile X Ataxia and Tremor Syndrome (FXTAS).

Anpac Bio Revenue Surges Nearly 300% After Signing 15th Global Fortune 500 Company Customer

SACRAMENTO, Calif., May 21, 2018 — Dr. Chris Yu, Chief Executive Officer of international life sciences corporation Anpac Bio-Medical Science Company, confirmed the company’s 2018 revenue vaulted nearly 300% over Anpac Bio’s 2017 revenue of the same period, immediately following news reports that Anpac Bio successfully secured its 15^th global Fortune 500 company customer – providing mass, early cancer, liquid biopsy screenings to support the new customer’s employee corporate wellness packages.

Yu also reported that Anpac Bio’s volume of, “Cancer Differentiation Analysis” (CDA) liquid biopsy tests processed in April 2018, set new global records for single day, single month, and single quarter, liquid biopsy screenings.

Described as “game changing”, and receiving the, “Breakthrough Innovation Award”, at the World Nobel Prize Laureate Summit; and named, “Most Promising Cancer Screening Company”, at the 2017 Global Precision Medicine IndustryAwards, Anpac Bio’s CDA technology effectively reinvents early cancer screening and detection.

By analyzing simple, standard, blood tests, and applying Anpac Bio’s proprietary, multi-level, multi-parameter, diagnostic algorithms, Anpac Bio’s CDA technology identifies cancer with measurably-greater accuracy than most current, conventional screening methods. And it does so without any harmful patient side effects; generating far fewer “false positives”; and at a cost substantially lower than traditional testing.

Comprehensive research validity data from 80,000+ cases processed to date demonstrate CDA diagnostics consistently detects up to 26 different cancers — with sensitivity and specificity rates of 75%-90% — usually identifying cancer at the earliest stages. Anpac Bio has filed 200+ CDA-related patent applications worldwide – 80+ issued currently.

While Anpac Bio is already, fully-commercialized and generating CDA liquid biopsy screening revenue, in response to the increased volume and demand for further services by medical, insurance, corporate, and individual customers, Anpac Bio has expanded (through sole proprietorship and joint venture agreements) its regulatory-agency certified laboratories worldwide; now also offering clinical biochemistry, clinical immunization, clinical molecular detection, and clinicopathology, among other services.

“Our company’s dramatic revenue generation year-over-year demonstrates our customers trust Anpac Bio’s CDA liquid biopsy technology to catch early-stage cancer and potentially save their employees’ lives,” reports Yu. “It also validates that our customers believe Anpac Bio’s suite of services, including CDA and other wellness testing options, are driving down their overall corporate healthcare costs. The acquisition of this 15th important customer proves Anpac Bio continues to build customer confidence.”

Anpac Bio Receives Exceptional Reimbursement Validation: Revenue in Insurance Sector Surges

Anpac Bio Receives Exceptional Reimbursement Validation

Revenue in Insurance Sector Surges

SACRAMENTO, CA | April 23, 2018 – Anpac Bio-Science Co., Ltd. (“Anpac Bio” hereafter), an international life science company with operations in both Asia and the US, announced today, that it recognized a 386% growth in insurance sector revenue in the first quarter of 2018 compared to 2017 for the same period. To date, Anpac Bio has nearly 10 major insurance as its customers, some of which are among the largest insurers in the world.

The core to Anpac Bio’s insurance reimbursement strategy is to demonstrate its significantly reduced costs over existing screening methods of early-stage cancer screening. The Company’s cancer differentiation analysis (CDA) screens can screen up to 26 cancer types simultaneously compared to only a single cancer type with traditional screening methods. Also, CDA is able to provide the maximum coverage at a minimum cost to carriers and individuals. Detecting cancers at the earliest stages offer the best chance for recovery and avoid extended, and costly, hospital stays.

Dr. Chris Yu, CEO of Anpac Bio, commented, “Anpac Bio continues to demonstrate sustainability in the marketplace in its partnerships with major insurance carriers that are built on an annual recurring revenue model. With the positive validation and surge in revenue we are receiving in Asia and a high level of interest from major medical institutions and healthcare providers in the United States, we continue to lead out with a significant advantage in cancer screening technology over the competition.”

Additionally, Anpac Bio offers its CDA technology directly to employers and is currently working with 14 global Fortune 500 companies as well as with national supplemental insurance carriers. By working through multiple channels, Anpac Bio believes it can be a commercial leader in the cancer diagnostic space.

Anpac Bio Wins 2018 International ‘BIG Innovation Award’

Sacramento, CA – Dr. Chris Yu, Chief Executive Officer of international life sciences corporation Anpac Bio-Medical Science Company, announced today that Anpac Bio has won the highly prestigious, international, “2018 BIG Innovation Award”.

Anpac Bio-Medical Science Company was named 2018 “BIG Innovation Award” Winner, in recognition of its global, “game-changing” research and services – particularly related to its breakthrough, “Cancer Differentiation Analysis” (CDA) liquid biopsy technology. The only company worldwide, fully-commercialized and earning revenue providing liquid biopsy screening, Anpac Bio’s proprietary (200+ patents filed to date) CDA identifies 26+ different, early-stage cancers from a single, low-cost blood test.

Recognizing the entire corporation for executing significant and consistent innovation through its worldwide research and services, Anpac Bio was particularly recognized as an international, “Big Innovation Award” winner due to its breakthrough and rapidly expanding, “Cancer Differentiation Analysis” (CDA) liquid biopsy technology.

Described as “game changing”, and also receiving the, “Breakthrough Innovation Award”, at the World Nobel Prize Laureate Summit ; and named, “Most Promising Cancer Screening Company”, at the 2017 Global Precision Medicine Industry Awards, Anpac Bio’s CDA liquid biopsy technology was presented the 2018 “Big Innovation Award”, in recognition of CDA’s reinvention of early cancer screening and detection.

By analyzing simple, standard, blood tests, and applying Anpac Bio’s proprietary, multi-level, multi-parameter, diagnostic algorithms, Anpac Bio’s CDA liquid biopsy technology identifies cancer with measurably-greater accuracy than most current, conventional screening methods. And it does so without any harmful side effects in patients; generating far fewer “false positives”; at a cost substantially lower than traditional testing; and generating results within minutes of sample submission.

Comprehensive research validity data from 80,000+ cases, and independently-corroborated by world-renowned hospitals and cancer research leaders, demonstrate Anpac Bio’s CDA diagnostics consistently detects 26+ cancers — with a sensitivity and specificity rate range of 75%-90%. Anpac Bio is the only company fully-commercialized and generating revenue providing liquid biopsy screening services. Over 200 CDA patent applications (70+ issued to date) have been filed worldwide.

“We are very proud that Anpac Bio is a 2018 ‘Big Innovation Award’ winner,” states Yu. “Our corporate culture at Anpac Bio encourages constant questioning and testing of the status quo. For dozens of years, the medical and research communities have applied the same, often toxic and ineffective methods to treat cancer. We invented CDA to challenge the status quo thinking of only treating cancer. CDA allows doctors and patients an innovative solution to beating cancer by catching the disease at its earliest stages. If cancer is caught early, the patient has the most, effective treatment options, and the best chance to beat the disease and live healthy lives. We are honored to receive the ‘Big Innovation Award’ recognizing our company and technology for being novel, positive, and disruptive in worldwide fight against cancer.”

Anpac Bio joins other prestigious, “The Big Innovation Award” winners, including Abbott technologies, Bechtel, Deutsche Telekom, Dow Chemicals, Drone Racing League, Harman, Hughes, Neeve Research, PepsiCo, Phononic, Resolute, Sleep Number, SpiderCloud Wireless, Symphony Clinical Research, TerraCycle, Procter & Gamble, and Vision Critical. Presented by the Business Intelligence Group, Organizations from across the globe submitted their recent innovations for consideration in the 2018 BIG Innovation Awards. Nominations were then judged by a select group of business leaders and industry executives considered international experts in the category they are judging.

“This year’s winners show the diversity of innovation and its impact on the economy, our cultures and the world as a whole,” said Maria Jimenez, chief operating officer of the Business Intelligence Group. “We are thrilled to be honoring Anpac Bio as they are leading by example and making real progress on improving the daily lives of so many.”

About Business Intelligence Group:

The Business Intelligence Group was founded with the mission of recognizing true talent and superior performance in the business world. Unlike other industry award programs , these programs are judged by business executives having experience and knowledge. The organization’s proprietary and unique scoring system selectively measures performance across multiple business domains and then rewards those companies whose achievements stand above those of their peers.

Super Model-Turned-Super Mogul Kathy Ireland Interviews Anpac Bio CEO For ‘Worldwide Business’

Super Model-Turned-SuperMogul Kathy Ireland Interviews Anpac Bio CEO For ‘WorldwideBusiness’

SACRAMENTO, Calif., April 20, 2018 /PRNewswire/ — Dr. Chris Yu, Chief Executive Officer of international life sciences corporation Anpac Bio-Medical Science Company, was interviewed this week by “Super Model-turned-Super Mogul” Kathy Ireland, for her award-winning “Worldwide Business with Kathy Ireland” multi-media program; to be aired on Reuter’s News, FOX News Business, and Bloomberg Business, among other global business and finance media outlets, later this year.

Invited by the acclaimed, celebrity business empire CEO to appear in a special, “Breakthroughs in Medical Innovation” segment of “Worldwide Business with Kathy Ireland”, Dr. Yu shared with Kathy and her audiences information about Anpac Bio’s proprietary “Cancer Differentiation Analysis” (CDA) liquid biopsy technology – the only such technology and testing fully-commercialized and available for patient screening worldwide.

Ireland featured Anpac Bio exclusively on “Worldwide Business” due to the company’s comprehensive research validity data from 80,000+ cases processed to date, demonstrating CDA diagnostics consistently detects over 26+ cancers — with a sensitivity and specificity rate range of 75%-90% — usually identifying the disease at its earliest stages from a single, standard blood test. And it does so without any harmful side effects in patients; generating far fewer “false positives” at a cost substantially lower than traditional testing; and generating results within minutes of sample submission.

Anpac Bio has filed over 200 CDA-related patent applications worldwide – 70+ issued currently; and maintains operations in seven sites, employing over 100 people globally.

Described as “game-changing” and receiving the “Breakthrough Innovation Award” at World Nobel Prize Laureate Summit; and named “Most Promising Cancer Screening Company” at the 2017 Global Precision Medicine Industry Awards, Anpac Bio’s CDA technology effectively reinvents early cancer screening and detection.

Kathy Ireland is the CEO of Kathy Ireland Worldwide. kiWW® is listed as one of the most powerful brands in the world by License Global Magazine. Kathy Ireland was named one of the 19 most influential women in licensing by License Global magazine and Fairchild Publications. Kathy graced the cover of Forbes Magazine twice (2012, 2016). kiWW® earns over $2.5 billion dollars in global retail sales annually; and has received multiple awards, including “Good Housekeeping Seals”. Kathy and kiWW® support many cancer-related charities such as the St. Jude Children’s Research Hospital. UCLA named Kathy one of the, “Top Ten Women’s Health Advocates in America” today.